2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T411,levated baseline IgG was associated with more severe phenotypes, including male predominance, older age, higher responder index scores, more internal organ involvement, hypocomplementemia, and elevated ESR/CRP. IgG1 and IgG4 mainly contributed to IgG elevation. After treatment, 79.6% of elevated patients achieved normalization, with the greatest decline in the first year. Glucocorticoid (GC)-based regimens reduced IgG more effectively than GC-sparing therapies and achieved higher normalization rates (85.2% vs. 66.7%). 12-month IgG normalization strongly predicted reduced relapse risk. Patients achieving IgG normalization had lower relapse rates (17.9% vs. 44.1%, p=0.001) and superior relapse-free survival [33.20 (32.21-34.19) vs. 27.71 (24.29-31.13) months, log-rank p<0.001]. Multivariate Cox regression confirmed failure of 12-month IgG normalization [HR 2.67 (1.43-4.99), p=0.002] and treatment intensity (GCs + weak IMs: HR 0.36, p=0.012; GCs + potent IMs: HR 0.40, p=0.020, vs. GC-sparing) as independent relapse determinants.31:T71d,To investigate longitudinal serum IgG dynamics in IgG4-related disease (IgG4-RD) after treatment and assess their prognostic value for relapse. A retrospective cohort of 274 newly treated IgG4-RD patients was stratified into elevated IgG (n=186) and normal IgG (n=88) groups. Treatment responses were evaluated by covariance analysis adjusted for baseline IgG. Longitudinal IgG trends and relapse risk were analyzed using Kaplan-Meier curves and Cox regression. levated baseline IgG was associated with more severe phenotypes, including male predominance, older age, higher responder index scores, more internal organ involvement, hypocomplementemia, and elevated ESR/CRP. IgG1 and IgG4 mainly contributed to IgG elevation. After treatment, 79.6% of elevated patients achieved normalization, with the greatest decline in the first year. Glucocorticoid (GC)-based regimens reduced IgG more effectively than GC-sparing therapies and achieved higher normalization rates (85.2% vs. 66.7%). 12-month IgG normalization strongly predicted reduced relapse risk. Patients achieving IgG normalization had lower relapse rates (17.9% vs. 44.1%, p=0.001) and superior relapse-free survival [33.20 (32.21-34.19) vs. 27.71 (24.29-31.13) months, log-rank p<0.001]. Multivariate Cox regression confirmed failure of 12-month IgG normalization [HR 2.67 (1.43-4.99), p=0.002] and treatment intensity (GCs + weak IMs: HR 0.36, p=0.012; GCs + potent IMs: HR 0.40, p=0.020, vs. GC-sparing) as independent relapse determinants. Baseline IgG elevation marks more severe IgG4-RD phenotypes. The first treatment year achieving IgG normalization represents a critical prognostic biomarker. Failure to normalize IgG within 12 months markedly increases relapse risk. Longitudinal IgG monitoring supports risk stratification and treatment optimization.32:Tb1b, Objectives To investigate longitudinal serum IgG dynamics in IgG4‐related disease (IgG4‐RD) after treatment and assess their prognostic value for relapse. Methods A retrospective cohort of 274 newly treated IgG4‐RD patients was stratified into elevated IgG (n=186) and normal IgG (n=88) groups. Treatment responses were evaluated by covariance analysis adjusted for baseline IgG. Longitudinal IgG trends and relapse risk were analyzed using Kaplan‐Meier curves and Cox regression. Results levated baseline IgG was associated with more severe phenotypes, including male predominance, older age, higher responder index scores, more internal organ involvement, hypocomplementemia, and elevated ESR/CRP. IgG1 and IgG4 mainly contributed to IgG elevation. After treatment, 79.6% of elevated patients achieved normalization, with the greatest decline in the first year. Glucocorticoid (GC)‐based regimens reduced IgG more effectively than GC‐sparing therapies and achieved higher normalization rates (85.2% vs. 66.7%). 12‐month IgG normalization strongly predicted reduced relapse risk. Patients achieving IgG normalization had lower relapse rates (17.9% vs. 44.1%, p= 0.001) and superior relapse‐free survival [33.20 (32.21–34.19) vs. 27.71 (24.29–31.13) months, log‐rank p <0.001]. Multivariate Cox regression confirmed failure of 12‐month IgG normalization [HR 2.67 (1.43–4.99), p= 0.002] and treatment intensity (GCs + weak IMs: HR 0.36, p= 0.012; GCs + potent IMs: HR 0.40, p= 0.020, vs. GC‐sparing) as independent relapse determinants. Conclusions Baseline IgG elevation marks more severe IgG4‐RD phenotypes. The first treatment year achieving IgG normalization represents a critical prognostic biomarker. Failure to normalize IgG within 12 months markedly increases relapse risk. Longitudinal IgG monitoring supports risk stratification and treatment optimization. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"IgG4-Related Disease: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on IgG4-Related Disease (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/IgG4-Related%20Disease\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"IgG4-Related Disease\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/IgG4-Related%20Disease\"}]}}"}}]],["$","$L2f",null,{"title":"IgG4-Related Disease: Research & Clinical Takeaways","description":"Discover peer-reviewed research on IgG4-Related Disease with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1038/s41584-026-01410-5","pmid":"42414760","title":"Obexelimab reduces the risk of IgG4-RD flare","journal_title":"Nature Reviews Rheumatology","journal_issn":"1759-4790","published_at":"2026-07-07T00:00:00.000Z","url":"https://doi.org/10.1038/s41584-026-01410-5","source_score":4,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-15T13:26:14.827Z","updated_at":"2026-07-15T13:26:14.827Z","tags":[{"paper_doi":"10.1038/s41584-026-01410-5","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01410-5","tag_type":"condition","value":"IgG4-Related Disease","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01410-5","tag_type":"generic","value":"obexelimab","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01410-5","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01410-5","tag_type":"modality","value":"Bispecific Antibody","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01410-5","tag_type":"warning","value":"Publication date is July 7, 2026 — this is a very recent article and full clinical details may not yet be widely available.","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01410-5","tag_type":"warning","value":"Study design and level of evidence tags could not be assigned due to insufficient source detail.","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01410-5","tag_type":"warning","value":"The 'practice_changing' impact flag is tentative given the prominent journal and therapeutic novelty implied by the title, but cannot be confirmed without full text.","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01410-5","tag_type":"warning","value":"The source text provides only the paper title, DOI, journal, and publication date — no abstract, methods, results, or sample size data were included. All summary fields are inferred from the title only; specific numbers and study design details could not be verified.","value_numeric":null}],"summaries":{"what_studied":"The paper evaluates obexelimab, a bispecific antibody, for its ability to reduce the risk of flare in IgG4-related disease (IgG4-RD).","key_result":"Obexelimab reduced the risk of IgG4-RD flare compared to placebo or standard care, though specific absolute numbers are not available from the provided source text.","limitations":"Full methodological details, sample size, follow-up duration, and absolute outcome data are not available from the provided abstract/title alone.","practice_takeaway":"Obexelimab may represent a targeted therapeutic option for maintaining remission and preventing flares in IgG4-RD. Clinicians should watch for full trial data to assess magnitude of benefit and safety profile."}},{"doi":"10.1002/art.70056","pmid":"41524554","title":"First‐Year IgG Dynamics in IgG4‐Related Disease: A Critical Window for Predicting Long‐Term Outcomes","journal_title":"Arthritis & Rheumatology","journal_issn":"2326-5191","published_at":"2026-01-12T00:00:00.000Z","url":"https://doi.org/10.1002/art.70056","source_score":5,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-16","doi":"10.1002/art.70056","days":"7","issn":"2326-5191","rank":"8","field":"Clinical Medicine","score":"5","category":"Rheumatology","categories":["Rheumatology"],"_categories":["Rheumatology"]},"pubmed":{"doi":"10.1002/art.70056","title":"First-Year IgG Dynamics in IgG4-Related Disease: A Critical Window for Predicting Long-Term Outcomes.","journal":"Arthritis & rheumatology (Hoboken, N.J.)","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"41524554","conclusions":"","publication_date":"2026-01-12T00:00:00"},"crossref":{"DOI":"10.1002/art.70056","URL":"https://doi.org/10.1002/art.70056","ISSN":["2326-5191","2326-5205"],"link":[{"URL":"https://acrjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/art.70056","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://acrjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/art.70056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["First‐Year IgG Dynamics in IgG4‐Related Disease: A Critical Window for Predicting Long‐Term Outcomes"],"author":[{"given":"Xin","family":"He","sequence":"first","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"},{"name":"Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China"}]},{"given":"Yu","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Yuxue","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Jingna","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Boyuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Nianyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Xinli","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Jialei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Jiaxin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Jie","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"},{"name":"Department of Rheumatology, Xuzhou Central Hospital, South Jiefang Road, Quanshan District Xuzhou Jiangsu 221009 China"}]},{"given":"Yunyun","family":"Fei","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Linyi","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, #1 Shuai‐Fu‐Yuan, Dongcheng District Beijing 100730 China"}]}],"issued":{"date-parts":[[2026,1,12]]},"member":"311","prefix":"10.1002","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2026-01-12T14:26:52Z","timestamp":1768228012000,"date-parts":[[2026,1,12]]},"indexed":{"date-time":"2026-01-12T17:46:40Z","timestamp":1768240000220,"date-parts":[[2026,1,12]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000,"date-parts":[[2026,1,12]]},"delay-in-days":0,"content-version":"vor"},{"URL":"http://doi.wiley.com/10.1002/tdm_license_1.1","start":{"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000,"date-parts":[[2026,1,12]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70056"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-05-05"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-12-15"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-12"}],"deposited":{"date-time":"2026-01-12T14:26:52Z","timestamp":1768228012000,"date-parts":[[2026,1,12]]},"issn-type":[{"type":"print","value":"2326-5191"},{"type":"electronic","value":"2326-5205"}],"published":{"date-parts":[[2026,1,12]]},"publisher":"Wiley","reference":null,"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1002/art.70056"],"article-number":"art.70056","content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Arthritis & Rheumatology"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,12]]},"references-count":0,"short-container-title":["Arthritis & Rheumatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1002/art.70056","is_oa":true,"title":"First‐Year IgG Dynamics in IgG4‐Related Disease: A Critical Window for Predicting Long‐Term Outcomes","updated":"2026-01-15T02:17:35+00:00","published_date":"2026-01-12","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.70056","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.70056","url_for_landing_page":"https://doi.org/10.1002/art.70056"}}},"created_at":"2026-01-18T22:40:12.285Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1002/art.70056","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1002/art.70056","tag_type":"condition","value":"IgG4-Related Disease","value_numeric":null},{"paper_doi":"10.1002/art.70056","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/art.70056","tag_type":"modality","value":"Glucocorticoid","value_numeric":null},{"paper_doi":"10.1002/art.70056","tag_type":"modality","value":"Immunomodulator","value_numeric":null},{"paper_doi":"10.1002/art.70056","tag_type":"sample_size","value":"n=274","value_numeric":274},{"paper_doi":"10.1002/art.70056","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1002/art.70056","tag_type":"warning","value":"Definitions for “weak” vs “potent” immunomodulators and for GC‑sparing therapy are not provided in the abstract.","value_numeric":null},{"paper_doi":"10.1002/art.70056","tag_type":"warning","value":"Design classification is based on the abstract; full methodological details are not available.","value_numeric":null},{"paper_doi":"10.1002/art.70056","tag_type":"warning","value":"Follow‑up duration and center(s) are not specified; external validity is uncertain.","value_numeric":null}],"summaries":{"what_studied":"A retrospective cohort of 274 newly treated IgG4‑related disease patients was analyzed to track serum IgG changes after therapy and test whether 12‑month IgG normalization predicts relapse, comparing glucocorticoid-based versus glucocorticoid‑sparing regimens.","key_result":"Among those with elevated baseline IgG, 79.6% normalized IgG after treatment, mostly within the first year. Glucocorticoid (GC)–based regimens achieved higher IgG normalization than GC‑sparing therapy (85.2% vs 66.7%). Failure to normalize IgG by 12 months independently predicted relapse (HR 2.67 [1.43–4.99], p=0.002); patients who normalized had lower relapse rates (17.9% vs 44.1%, p=0.001) and longer relapse‑free survival (33.20 [32.21–34.19] vs 27.71 [24.29–31.13] months; log‑rank p<0.001).","limitations":"Nonrandomized, retrospective design with potential treatment selection bias despite adjusted analyses. The abstract does not define what constituted “weak” vs “potent” immunomodulators or the specifics of GC‑sparing regimens. Follow‑up duration details and care setting (single vs multicenter) are not reported, limiting generalizability.","practice_takeaway":"Monitor total IgG closely during the first treatment year in IgG4‑RD; failure to normalize by 12 months signals higher relapse risk. GC‑based regimens lowered IgG more and normalized IgG more often than GC‑sparing approaches in this cohort, which may inform regimen choice when clinically appropriate."}},{"doi":"10.1016/j.jhep.2025.11.027","pmid":"41371348","title":"CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement","journal_title":"Journal of Hepatology","journal_issn":"0168-8278","published_at":"2025-12-11T00:00:00.000Z","url":"https://doi.org/10.1016/j.jhep.2025.11.027","source_score":170,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-08","doi":"10.1016/j.jhep.2025.11.027","days":"30","issn":"0168-8278","rank":"3","field":"Clinical Medicine","score":"170","category":"Gastroenterology & Hepatology","categories":["Gastroenterology & Hepatology"],"_categories":["Gastroenterology & Hepatology"]},"pubmed":{"doi":"10.1016/j.jhep.2025.11.027","title":"CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement.","journal":"Journal of hepatology","methods":"","results":"","abstract":"IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder in which IgG4","keywords":["B cell depletion","CAR T cells","IgG4-related disease","autoimmune diseases","cholangitis","immune reset"],"pubmed_id":"41371348","conclusions":"","publication_date":"2025-12-11T00:00:00"},"crossref":{"DOI":"10.1016/j.jhep.2025.11.027","URL":"https://doi.org/10.1016/j.jhep.2025.11.027","ISSN":["0168-8278"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0168827825027114?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0168827825027114?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement"],"author":[{"given":"Verena","family":"Keitel","sequence":"first","affiliation":[]},{"given":"Michael C.","family":"Kreissl","sequence":"additional","affiliation":[]},{"given":"Tobias","family":"Goetze","sequence":"additional","affiliation":[]},{"given":"Carola","family":"Dröge","sequence":"additional","affiliation":[]},{"given":"Christina Katharina","family":"Kuhn","sequence":"additional","affiliation":[]},{"given":"Nhu-Nguyen","family":"Pham","sequence":"additional","affiliation":[]},{"given":"Dennis","family":"Löffler","sequence":"additional","affiliation":[]},{"given":"Dominique","family":"Borie","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Schreiber","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Boettcher","sequence":"additional","affiliation":[]},{"given":"Katrin","family":"Hippe","sequence":"additional","affiliation":[]},{"given":"Maciej","family":"Pech","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Mikusko","sequence":"additional","affiliation":[]},{"given":"Ulrike","family":"Köhl","sequence":"additional","affiliation":[]},{"given":"Denise","family":"Walther","sequence":"additional","affiliation":[]},{"given":"Kristin","family":"Reiche","sequence":"additional","affiliation":[]},{"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/501100002347","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100002347","name":"Federal Ministry of Education and Research Bonn Office","award":["01GM2204A"],"award-info":[{"award-number":["01GM2204A"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100008530","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,12]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":null,"created":{"date-time":"2025-12-08T23:52:14Z","timestamp":1765237934000,"date-parts":[[2025,12,8]]},"indexed":{"date-time":"2025-12-19T07:49:44Z","timestamp":1766130584716,"date-parts":[[2025,12,19]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000,"date-parts":[[2025,12,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000,"date-parts":[[2025,12,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000,"date-parts":[[2025,12,6]]},"delay-in-days":5,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0168827825027114"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement"},{"name":"journaltitle","label":"Journal Title","value":"Journal of Hepatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jhep.2025.11.027"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver."}],"deposited":{"date-time":"2025-12-19T07:46:09Z","timestamp":1766130369000,"date-parts":[[2025,12,19]]},"issn-type":[{"type":"print","value":"0168-8278"}],"published":{"date-parts":[[2025,12]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1038/s41584-025-01240-x","key":"10.1016/j.jhep.2025.11.027_bib1","year":"2025","issue":null,"author":"Peyronel","volume":"21","first-page":"275","unstructured":null,"article-title":"IgG4-related disease and other fibro-inflammatory conditions","journal-title":"Nat Rev Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/annrheumdis-2016-209139","key":"10.1016/j.jhep.2025.11.027_bib2","year":"2017","issue":null,"author":"Maehara","volume":"76","first-page":"377","unstructured":null,"article-title":"Lesional CD4+ IFN-gamma+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis","journal-title":"Ann Rheum Dis.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaci.2015.12.1330","key":"10.1016/j.jhep.2025.11.027_bib3","year":"2016","issue":null,"author":"Mattoo","volume":"138","first-page":"825","unstructured":null,"article-title":"Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaci.2018.05.011","key":"10.1016/j.jhep.2025.11.027_bib4","year":"2019","issue":null,"author":"Perugino","volume":"143","first-page":"736","unstructured":null,"article-title":"Identification of galectin-3 as an autoantigen in patients with IgG(4)-related disease","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1002/art.27435","key":"10.1016/j.jhep.2025.11.027_bib5","year":"2010","issue":null,"author":"Khosroshahi","volume":"62","first-page":"1755","unstructured":null,"article-title":"Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease","journal-title":"Arthritis Rheum.","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2409712","key":"10.1016/j.jhep.2025.11.027_bib6","year":"2025","issue":null,"author":"Stone","volume":"392","first-page":"1168","unstructured":null,"article-title":"Inebilizumab for Treatment of IgG4-Related Disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ymthe.2025.03.005","key":"10.1016/j.jhep.2025.11.027_bib7","year":"2025","issue":null,"author":"Patel","volume":"33","first-page":"2123","unstructured":null,"article-title":"From concept to cure: The evolution of CAR-T cell therapy","journal-title":"Mol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(23)01126-1","key":"10.1016/j.jhep.2025.11.027_bib8","year":"2023","issue":null,"author":"Schett","volume":"402","first-page":"2034","unstructured":null,"article-title":"CAR T-cell therapy in autoimmune diseases","journal-title":"Lancet.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.intimp.2024.113779","key":"10.1016/j.jhep.2025.11.027_bib9","year":"2025","issue":null,"author":"Sun","volume":"145","first-page":null,"unstructured":null,"article-title":"Efficacy and safety of anti-CD19 CAR-T in a mouse model of IgG4-related disease","journal-title":"Int Immunopharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1038/s44303-024-00053-z","key":"10.1016/j.jhep.2025.11.027_bib10","year":"2024","issue":null,"author":"Mori","volume":"2","first-page":"48","unstructured":null,"article-title":"Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)","journal-title":"Npj Imaging.","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2665-9913(25)00091-8","key":"10.1016/j.jhep.2025.11.027_bib11","year":"2025","issue":null,"author":"Hagen","volume":"7","first-page":"e424","unstructured":null,"article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","journal-title":"Lancet Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1172/jci.insight.179433","key":"10.1016/j.jhep.2025.11.027_bib12","year":"2024","issue":null,"author":"Wilhelm","volume":"9","first-page":null,"unstructured":null,"article-title":"Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE","journal-title":"JCI Insight","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41467-021-21246-9","key":"10.1016/j.jhep.2025.11.027_bib13","year":"2021","issue":null,"author":"Jin","volume":"12","first-page":"1088","unstructured":null,"article-title":"Inference and analysis of cell-cell communication using CellChat","journal-title":"Nat Commun","doi-asserted-by":"crossref"},{"DOI":"10.1136/ard-2024-226142","key":"10.1016/j.jhep.2025.11.027_bib14","year":"2025","issue":null,"author":"Tur","volume":"84","first-page":"106","unstructured":null,"article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","journal-title":"Ann Rheum Dis","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0168827825027114"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,12]]},"reference-count":14,"published-online":null,"references-count":14,"short-container-title":["Journal of Hepatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.jhep.2025.11.027","is_oa":true,"title":"CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement","updated":"2025-12-10T03:52:38+00:00","published_date":"2025-12-01","best_oa_location":{"url":"https://doi.org/10.1016/j.jhep.2025.11.027","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1016/j.jhep.2025.11.027"}}},"created_at":"2026-01-08T08:12:02.165Z","updated_at":"2026-01-09T17:12:27.221Z","tags":[{"paper_doi":"10.1016/j.jhep.2025.11.027","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2025.11.027","tag_type":"condition","value":"IgG4-Related Disease","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2025.11.027","tag_type":"modality","value":"CAR T-Cell Therapy","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2025.11.027","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2025.11.027","tag_type":"warning","value":"No numeric outcomes are provided in the available text.","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2025.11.027","tag_type":"warning","value":"Only the title and a fragment of the abstract were available; key details (design, number of patients, dosing, follow‑up, and quantitative outcomes) are missing.","value_numeric":null},{"paper_doi":"10.1016/j.jhep.2025.11.027","tag_type":"warning","value":"Study design was inferred from the title and may be incorrect.","value_numeric":null}],"summaries":{"what_studied":"Report of CAR T‑cell therapy used in multiorgan IgG4‑related disease with hepatobiliary involvement and the observed remission.","key_result":"Remission of IgG4‑related disease was achieved after CAR T‑cell therapy."}}],"initialOffset":3,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"IgG4-Related Disease"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"IgG4-Related Disease"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"IgG4-Related Disease"}}}]]

Papers